Retrospective cohort study of correlation between immune check point molecular inhibitor and response factor, side effect, and post treatment

Trial Profile

Retrospective cohort study of correlation between immune check point molecular inhibitor and response factor, side effect, and post treatment

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2017 Results assessing predictive factors for poor progression free survival published in the Anticancer Research
    • 01 Oct 2017 Results (n=199) assessing the relationship between chemotherapy immediately before nivolumab and outcomes thereafter published in the Anticancer Research
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top